Derivation of AZD5335, a Novel FRα-Targeted TOP1i-Loaded ADC, for the Treatment of FRα-Expressing Cancers.
Zoeller JJ, Tammali R, Dodd RB, Patel NV, Andoni A, Bisha I, Cronin S, De Almeida A, Lee N, Meekin JH 3rd, Tilmont I, Gasper D, Lan L, Cox M, Thomas T, Ward C, Chesebrough J, Anderton J, Neal F, Zenonos Z, Shandilya H, Chooi KP, Pugh K, Saleh A, Wang J, Mitchell P, Naseer H, Beaumont K, Hood J, Myers C, Christ S, Dino I, Guza X, Falck T, Lehmann M, Sargeant R, Godfrey L, Recolin B, Brier T, Turner S, Rosfjord E, Fraenkel PG, Cosulich S, Gymnopoulos M, Hurt E, Sapra P.
Zoeller JJ, et al. Among authors: saleh a.
Clin Cancer Res. 2025 Dec 15;31(24):5261-5275. doi: 10.1158/1078-0432.CCR-25-1749.
Clin Cancer Res. 2025.
PMID: 41091103
Free PMC article.